Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report

Publisher Website
Google Scholar
Abstract
Patients (12) with metastatic transitional cell carcinoma from the urinary bladder were treated with a combination chemotherapy program of cisplatinum, cyclophorphamide and doxorubicin hydrochloride (CISCA). Ten patients had conditions for which a response to therapy could be determined and 9 achieved an objective response (1 complete response, 8 partial responses). Two additional patients with metastatic transitional cell carcinoma from the renal pelvis were treated and 1 achieved a partial response. CISCA combination chemotherapy gave the highest response rate of any protocol thus far tested in advanced, metastatic urinary tract carcinoma.